HOME >> BIOLOGY >> NEWS
Boston chemist wins national award for research with enzymes, antibiotics

Christopher T. Walsh of Boston will be honored March 25 by the world's largest scientific society for his broad-ranging insights into how the enzymes of organisms drive chemical reactions, including how the antibiotic of last resort, vancomycin, can be defeated by bacterial enzymes. He will receive the 2003 Alfred Bader Award in Bioorganic Chemistry from the American Chemical Society at its national meeting in New Orleans.

In more than 35 years of research Walsh has studied a variety of enzymes, a class of proteins in humans and other organisms that orchestrate the breakdown of food, the assembly of hormones, the coagulation of blood, and the processing of neurological signals and many other functions.

"We're interested in what enzymes actually do, how they do it, what goes wrong and whether we can fix it," said Walsh, a biological chemist and professor at Harvard Medical School. About one-third of human diseases start with some malfunction in one of the body's thousands of enzymes.

Most recently his research team has focused on antibiotics, drugs that fight bacterial infections by selectively blocking bacterial enzymes while leaving human ones alone. For example, vancomycin kills bacteria by inhibiting their enzymes' ability to stitch together their cell walls.

In the early 1990s Walsh and his group discovered and characterized how some bacteria were able to evolve resistance to vancomycin's action -- by changing the shape of their strands of cell wall. Their fundamental insights have helped drug companies design new variants of vancomycin, some of which are now in human trials.

Walsh, who originally planned to go to medical school after college, was an undergraduate researcher in the laboratory of Konrad Bloch when he won the Nobel Prize in Physiology or Medicine in 1964 for his cholesterol research. "I'm sure that had something to do with my deciding I liked research better," Walsh said.

One year later he received h
'"/>

Contact: Allison Byrum
a_byrum@acs.org
202-872-4400
American Chemical Society
4-Mar-2003


Page: 1 2

Related biology news :

1. Springtime blooms seen earlier now than in the past, say Boston University biologists
2. Childrens Hospital Boston receives more than $10 million to help make smallpox vaccine safer
3. NIH funds new Boston College-Boston University study of B-1a cell associated with leukemia
4. The American Society for Biochemistry and Molecular Biology meets in Boston
5. Boston chemist wins national award for protein research
6. Tufts civil engineer predicts Bostons rising sea levels could cause billions of dollars in damage
7. Childrens Hospital Boston researchers regenerate zebrafish heart muscle
8. Microorganisms are cleaning up Boston Harbor, UMass study finds
9. Highlights of American Chemical Societys national meeting in Boston
10. Childrens Hospital Boston researchers use therapeutic cloning to create functional tissue in cows
11. Study by Boston College chemistry team shows critical role of water in protein function

Post Your Comments:
(Date:7/23/2014)... Chrysomya megacephala is commonly found in dead bodies ... time of death, referred to as the post mortem ... C. megacephala from Tamil Nadu is provided for ... characterization through generation of DNA barcoding. This study, significant ... Biodiversity Data Journal . , Chrysomya megacephala ...
(Date:7/23/2014)... New Rochelle, NY -- The potential for clinical ... for transplant-based therapeutic strategies has previously been hindered ... the development of tumors. The ability to use ... for the treatment of heart disease, specifically acute ... Stem Cells and Development , a peer-reviewed ...
(Date:7/23/2014)... MINNETONKA, Minn. , July 23, 2014 /PRNewswire/ ... technology company specializing in clinical study management systems, ... West , a proven life sciences industry executive ... named Chief Operating Officer (COO).  Clareece will be ... and sales growth, operational efficiency and quality product/service ...
Breaking Biology News(10 mins):Dead body feeding larvae useful in forensic investigations 2MedNet Appoints Clareece West As Chief Operating Officer 2
(Date:7/23/2014)... July 23, 2014 ... of Trendlines Agtech , announced it has ... Israel,s leading agricultural thermoplastics applications companies. ... Valentis,s technology combines nanocrystalline cellulose (NCC), a biodegradable, ... additional nanoparticles to produce highly improved polymeric films. ...
(Date:7/23/2014)... regulated information -- UCB today announced an important advance ... topline results from the latest Phase 3 study ... evaluate the efficacy and safety of brivaracetam ... to placebo, as adjunctive treatment in adult focal ... despite treatment with one or two concomitant antiepileptic ...
(Date:7/23/2014)... 2014  Sofinnova Ventures, a Menlo Park ... of Sofinnova Venture Partners IX, L.P. at the hard ... initial fund target of $425 million. Sofinnova ... Consistent with recent funds, SVP IX will provide capital ... along with select investments in earlier stage opportunities. Investments ...
(Date:7/23/2014)... 2014 OncLive® is pleased to ... joined its Strategic Alliance Partnership program. , ... UNC Lineberger will have the opportunity to work ... its cutting-edge research initiatives, community-directed cancer prevention programs, ... work with OncLive to educate their peers by ...
Breaking Biology Technology:Valentis Nanotech Signs MOU to Integrate Technology in Thermoplastics Production 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 4Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 5Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 6Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 7Sofinnova Raises $500 Million Biotech Venture Fund 2OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center 2OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center 3
Cached News: